Drug Target Review

SEPTEMBER 22, 2023

Organoid technologies are becoming an invaluable solution for preclinical research, with the ability to augment the development of personalised medicine, drug discovery and gene therapies. 5 Organoids are recognised as New Alternative Methods (NAMs) in drug development. billion by 2030.

Clinical Research 116

Clinical Research Research Drug Development Molecular Biology 116

Drug Target Review

FEBRUARY 19, 2024

I always found science fascinating, but I really fell in love with it in high school when I was introduced to biochemistry and molecular biology. Biochemistry and molecular biology fascinated me in school. There are many failures and setbacks in drug discovery, and you need a lot of resilience to keep going.

Molecular Biology 110

Molecular Biology Science Protein Expression Production 110

BMG Labtech

MARCH 11, 2024

They are often the method of choice to detect or measure specific biological molecules (analytes) for diagnostics, drug discovery or fundamental research. This is reflected in scientific discoveries across many research disciplines including immunology , molecular biology , medicine, and diagnostics.

Vaccine 98

Vaccine Molecular Biology Laboratories Virus 98

Drug Target Review

MARCH 15, 2024

The discovery and development phases of biotherapeutic drugs leverage multiple technologies and processes across upstream and downstream stages of the bioprocess workflow. Selecting the appropriate upstream tools is key to avoiding challenges downstream, ultimately reducing development costs and delays in drug approvals.

Engineering 105

Engineering Molecular Biology Protein Expression Medical Schools 105

The Pharma Data

FEBRUARY 25, 2022

Several FDA-approved drugs – including for type 2 diabetes, hepatitis C and HIV – significantly reduce the ability of the Delta variant of SARS-CoV-2 to replicate in human cells, according to new research led by scientists at Penn State. 25) in the journal Communications Biology. ” The findings published today (Feb.

FDA Approval 52

FDA Approval FDA Molecular Biology Virus 52

Elrig

APRIL 29, 2024

Webinar | Ai At The Frontier: Empowering Early Career Professionals In Drug Discovery WEBINAR – ARE YOU CURIOUS ABOUT THE CUTTING-EDGE INTERSECTION OF ARTIFICIAL INTELLIGENCE AND DRUG DISCOVERY? Are you curious about the cutting-edge intersection of Artificial Intelligence and Drug Discovery?

Bioinformatics 59

Bioinformatics Drugs Molecular Biology Cell Based Assays 59

Drug Target Review

MAY 27, 2024

How does the company see antibody-drug conjugates (ADCs) fitting into this approach? Antibody-drug conjugates have seen explosive growth in the last few years which has materialised with numerous clinical trials demonstrating meaningful improvements in survival.

Clinical Trials 59

Clinical Trials Science Molecular Biology Bioinformatics 59

Drug Target Review

OCTOBER 3, 2024

Since the 1970s, when hybridoma technology enabling the generation of monoclonal antibodies (mAbs) was first developed, 1 antibody-based therapeutics have become one of the most rapidly growing drug categories, with applications across cancer indications, immune disorders and infections.

Molecular Biology 52

Molecular Biology Pharmacokinetics Laboratories Animal Testing 52

Alta Sciences

JUNE 11, 2024

One thing is for sure—regardless of how the field evolves around regulation requirements, Altasciences has the experience and range of capabilities to take on your gene therapy drug development programs. Connect with Dr. Turcotte on LinkedIn. Image Thumbnail_Blog_June 2024.jpg

Therapies 52

Therapies Molecular Biology Immune Response Science 52

Drug Target Review

JUNE 19, 2024

From 1999 until 2000, he worked at the University of California, San Diego (UCSD) Department of Technology Transfer & Intellectual Property Services and from 1996 to 1999 he conducted drug development research for Neurocrine Biosciences, Inc. Mr Culley served on the Board of Orphagen Pharmaceuticals, Inc.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

Codon

FEBRUARY 13, 2024

doi: 10.2210/rcsb_pdb/goodsell-gallery-048 The Virus that Cures It’s been over 25 years since the science magazine Discover first ran an extraordinary article about how a long-forgotten medical treatment, used in the former Soviet country of Georgia, could save us from the growing threat of untreatable, drug-resistant infections.

Therapies 125

Therapies Virus DNA Clinical Trials 125

Vial

MARCH 1, 2024

Leading Global CROs To advance new therapies, pharma, biotech, and medical device sponsors engage CROs to help navigate the complex landscape of drug development and regulatory pathways and to manage clinical trials efficiently, ethically, and in compliance with good clinical practice ( GCP ) standards.

Clinical Trials 52

Clinical Trials Clinical Research Trials Laboratories 52

The Pharma Data

JANUARY 6, 2021

The approach used to turn botulinum toxin into a kind of Trojan horse that delivers a cargo into neurons has enormous potential for future drug development,” noted Thomas C. “This is a landmark study in converting the power of lethal botulinum neurotoxins into therapies. Südhof, M.D.,

Science 52

Science Molecular Biology Treatment Production 52

Drug Target Review

OCTOBER 25, 2024

8 In what ways does the integration of hypothesis-driven and hypothesis-free approaches enhance our ability to identify novel biomarkers and drug targets for Alzheimer’s disease? Integration” is the key word here, as we need both approaches to enhance identification of biomarkers and drug targets for Alzheimer’s disease. Bennett, D.

Disease 59

Disease Clinical Trials Therapies Science 59

Alta Sciences

AUGUST 21, 2024

Internships at Altasciences: Q&A With Our Summer Interns nbartlett Thu, 08/22/2024 - 04:44 Internships at Altasciences are more than just a stepping stone—they’re a gateway to real-world-experience and professional growth, giving the next generation opportunities to help shape progress in the drug development industry.

International 40

International Laboratories Science Molecular Biology 40

The Pharma Data

JANUARY 4, 2021

Longwood has a robust research department with 7 post doctorates conducting research in molecular biology, microbiology, genomics, cancer biology, and immunology and publishing over 75 publications in different scientific journals in the past 5 years. Barber also serves on Kiromic’s Scientific Advisory Board.

Therapies 40

Therapies Molecular Biology Immune Response Science 40

The Pharma Data

JANUARY 25, 2021

With a background in molecular biology and clinical chemistry, Dr. Zetterberg has spent the last 20 years focusing on the development of biomarkers for Alzheimer’s disease, Parkinson’s disease and other brain disorders. . About NervGen.

Disease 40

Disease Clinical Development Molecular Biology Treatment 40

Drug Target Review

FEBRUARY 15, 2024

To survive this era, governments, multi-lateral organisations, foundations, and industry will need to work collectively on researching and developing new drugs that can prevent or treat a broad range of epidemic-prone pathogens, some of which have not yet been identified. The scientific challenges are enormous.

Drug Development 122

Drug Development Virus Vaccine Government 122

Drug Target Review

FEBRUARY 19, 2025

His areas of expertise include biologic drug development, cell and gene therapies, and gene editing. Cedrone holds a PhD in molecular biology and enzyme engineering from Marseille University, France.

Therapies 59

Therapies Molecular Biology Regulations Packaging 59